VirTra, Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VirTra, Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 26, 2026 |
| FY2024 | Mar 31, 2024 | $748.0K | Mar 27, 2025 |
| FY2025 | Dec 31, 2023 | $748.0K | Mar 26, 2026 |
| FY2017 | Dec 31, 2017 | $16.52M | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $15.65M | Mar 30, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.40M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $26.35M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $38.29M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $28.30M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $24.43M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $19.09M | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | $18.71M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $18.08M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $16.52M | Apr 1, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.20M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $19.41M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $26.91M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $16.25M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $11.41M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $11.90M | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | $9.71M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $11.05M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $10.23M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $9.68M | Mar 30, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($792.4K) | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | ($388.6K) | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $175.3K | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | $1.26M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($888.3K) | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | $583.1K | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | $1.20M | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | $468.2K | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $8.65M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $1.96M | Apr 1, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $437.5K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.00M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $9.89M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $2.59M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.45M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.23M | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | $262.3K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $999.9K | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $1.31M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.13M | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.38M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.00M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.79M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $2.61M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.87M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.60M | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | $1.35M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.36M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $1.29M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.08M | Mar 30, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.59M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.26M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.68M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($2.69M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($125.7K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.25M | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | ($1.91M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.83M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $2.65M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.75M | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.52M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.85M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.13M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.22M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.45M | Mar 31, 2023 |
| FY2020 | Dec 31, 2019 | $171.5K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $292.8K | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $133.8K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $309.5K | Mar 30, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.14M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $64.95M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $70.38M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $53.81M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $49.58M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $22.75M | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | $17.46M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $15.22M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $14.85M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $9.91M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.54M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $19.76M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $27.01M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $20.13M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $18.35M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $11.09M | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | $7.28M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $4.62M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $4.46M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.50M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.59M | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | $46.33M | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $46.84M | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | $46.49M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $45.19M | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | $45.65M | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | $44.91M | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | $43.49M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $42.87M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $33.68M | Mar 27, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.53M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.28M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $11.41M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.26M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $304.2K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.24M) | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | ($3.71M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($3.64M) | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | ($4.46M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($7.72M) | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.59M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $18.04M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $18.85M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $13.48M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $19.71M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $6.84M | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | $1.42M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $2.50M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $5.08M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.70M | Mar 30, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.54M | Mar 26, 2026 |
| FY2024 | Dec 31, 2024 | $7.80M | Mar 27, 2025 |
| FY2025 | Dec 31, 2023 | $128.8K | Mar 26, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 30, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 30, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.30M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 11.26M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 11.11M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 10.90M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 10.90M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 7.78M | Aug 2, 2022 |
| FY2020 | Dec 31, 2019 | 7.75M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 7.82M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | 7.90M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 7.93M | Mar 30, 2018 |